ScholarIQanswers from OpenAlex
Ono Pharmaceutical
FunderResearch funding and supported work
Ono Pharmaceutical is a funder indexed in ScholarIQ from OpenAlex.
How many works does Ono Pharmaceutical have?
ScholarIQindexed works
Ono Pharmaceutical has 4,140 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Ono Pharmaceutical?
ScholarIQopenalex
The OpenAlex for Ono Pharmaceutical is on the source record.
What is the ROR of Ono Pharmaceutical?
ScholarIQror
The ROR for Ono Pharmaceutical is on the source record.
What are the most-cited papers on Ono Pharmaceutical?
ScholarIQmost cited works
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Helen M. Colhoun, Ildiko Lingvay, Paul Brown, John Deanfield, Kirstine Brown‐Frandsen, Steven E. Kahn, Jorge Plutzky, Koichi Node, Alexander Parkhomenko, Lars Rydén, John Wilding, Johannes F.E. Mann, Katherine R. Tuttle, Thomas Idorn, Naveen Rathor, A. Michael Lincoff
KDIGO 2025 clinical practice guideline for the evaluation, management, and treatment of autosomal dominant polycystic kidney disease (ADPKD): executive summary
Vicente E. Torres, Curie Ahn, Thijs R.M. Barten, Godela Brosnahan, Melissa A. Cadnapaphornchai, Arlene B. Chapman, Émilie Cornec-Le Gall, Joost P.H. Drenth, Ron T. Gansevoort, Peter C. Harris, Tess Harris, Shigeo Horie, Max C. Liebau, Michele Liew, Andrew Mallett, Changlin Mei, Djalila Mekahli, Dwight Odland, Albert Ong, Luiz F. Onuchic, York Pei, Ronald D. Perrone, Gopala K. Rangan, Brian Rayner, Roser Torrá, Ethan M. Balk, Craig E. Gordon, Amy Earley, Reem A. Mustafa, Olivier Devuyst
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial
Natalie Staplin, Richard Haynes, PK Judge, Christoph Wanner, Julie Green, Jonathan Emberson, David Preiss, KJ Mayne, SYA Ng, Emily Sammons, Dandan Zhu, Michael Hill, W. Grant Stevens, Karl Wallendszus, S Brenner, AK Cheung, Zhihong Liu, J Li, LS Hooi, Wenjun Liu, Takashi Kadowaki, Masaomi Nangaku, Adeera Levin, David Z.I. Cherney, Aldo P. Maggioni, Roberto Pontremoli, Rajat Deo, Shinichi Goto, Xavier Rosselló, Katherine R. Tuttle, Dominik Steubl, Michaela Petrini, Siegfried Seidi, Martin Landray, Colin Baigent, WG Herrington, Sharirose Abat, Riaz Rahman, Rizna Abdul Cader, MI Abdul Hafidz, MZ Abdul Wahab, NK Abdullah, Talal Abdulsamad, Masami Abe, Ned Abraham, Sarah Acheampong, P Achiri, JA Acosta, A A Adeleke, Vicki Adell, R Adewuyi-Dalton, Nihad Adnan, A Africano, Mohsen Agharazii, Frank G. Aguilar, A Aguilera, M Ahmad, MK Ahmad, NA Ahmad, NH Ahmad, NI Ahmad, Norazinizah Ahmad Miswan, H Ahmad Rosdi, Iffat Ahmed, Sofia B. Ahmed, Sofia B. Ahmed, Joan Aiello, Alastair Aitken, R AitSadi, Sendogan Aker, S Akimoto, Akinwande A. Akinfolarin, S. Akram, Federico Alberici, Christian Albert, Luke Aldrich, M Alegata, Lacy M. Alexander, S Alfaress, Mohammad Alhadj Ali, A Ali, A Ali, Radica Z. Alicic, Arta Aliu, Ricardo López Almaraz, Rashid Almasarwah, Jussara Carnevale de Almeida, Alessia Aloisi, Laith Al‐Rabadi, Mark Dominik Alscher, Pedro Álvarez, Bader Al-Zeer, M. Ochoa de Olza Amat, Christopher S. Ambrose, Hany Ammar, Yu An, L Andriaccio, K Ansu, A Apostolidi, N. Arai
Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Eplerenone in Japanese Patients With Chronic Heart Failure (J-EMPHASIS-HF)
Hiroyuki Tsutsui, Hiroshi Ito, Masafumi Kitakaze, Issei Komuro, Toyoaki Murohara, Tohru Izumi, Kenji Sunagawa, Yoshio Yasumura, Masafumi Yano, K. Yamamoto, Tsutomu Yoshikawa, Takayoshi Tsutamoto, Junwei Zhang, Akifumi Okayama, Yoshihiko Ichikawa, Kazuhiro Kanmuri, Masunori Matsuzaki, for the J-EMPHASIS-HF Study Group
Hemolysis induced by SARS-CoV-2 mRNA vaccination in patients with paroxysmal nocturnal hemoglobinuria
Yuya Kamura, Tatsuhiro Sakamoto, Yasuhisa Yokoyama, Hidekazu Nishikii, Mamiko Sakata-Yanagimoto, Shigeru Chiba, Naoshi Obara